⌕
Pharming Group · PHAR · Nasdaq
Tenet 41 · Weak
Compare
$12.59−0.08%At closeTenet 41 · Weak
$12.59−0.01 (−0.08%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Pharming Group (PHAR) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue compounds ~5.7%/yr (FY21→FY25), net margin 1.0%. Worth your attention in FY25: Share count (+8.2%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲35.1%
247.9
FY21→FY25CAGR +5.7%/yr
Net income ($M)—
2.5
one-off year: see footnoteCAGR −36.9%/yr
Free cash flow ($M)—
—
no FY25 valueCAGR —
Diluted EPS—
0.00
FY21→FY25CAGR −35.4%/yr
What the receipts whisper · what a headline number hides
Share count
+8.2%

648.7mn → 701.7mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)247.9Revenue−45.5COGS330.6Gross profit−100.4R&D−80.0SG&A22.1Op income−19.6Tax & other2.5Net income

1¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
18013590450%FY21FY25

Over this window: gross 89.4% → 133.4%. Net margin 1.0% is more than double the sector median.

The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
Line itemFY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
247.9183.5124.6205.6198.9▲35.1%+5.7%
Cost of revenue
45.535.425.217.621.0▲28.5%+21.3%
Gross profit
330.6261.8220.1188.1177.7▲26.3%+16.8%
Research & development
100.483.168.952.570.4▲20.7%+9.3%
Selling, general & admin
80.070.755.946.037.0▲13.2%+21.3%
Total operating expenses
180.3153.8124.8184.3166.8▲17.2%+2.0%
Operating incomefeeds ROC rank
22.1−5.7−25.418.213.6—+13.0%
Other income, net
−9.3−2.813.3−3.29.5——
Pretax income
12.8−8.5−12.015.023.1—−13.6%
Income tax
10.33.3−1.51.37.1▲207.9%+9.8%
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings
2.5−11.8−10.513.716.0—−36.9%
Per share
Diluted EPSbuyback-sensitive
0.00−0.02−0.020.020.02—−35.4%
Diluted shares (mn)
701.68680.31671.07656.35648.75▲3.1%+2.0%
Margins
Gross margin100th pct in Healthcare
133.4%142.7%176.6%91.5%89.4%▼9.3pp+44.0pp
Operating margin
8.9%−3.1%−20.3%8.9%6.8%▲12.0pp+2.1pp
Net margin54th pct in Healthcare
1.0%−6.5%−8.5%6.7%8.0%▲7.5pp−7.0pp
FY21 effective tax rate was 31% vs a 12% norm for this window, likely a one-time item; see the filing.FY24 effective tax rate was −39% vs a 12% norm for this window, likely a one-time item; see the filing.
FY18 – FY20 · 3 more years
Unlock the full history →
3 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-04-13 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Pharming Group's revenue last fiscal year?

Pharming Group reported revenue of $247.9M in fiscal 2025, up 35.1% from fiscal 2024.

What was Pharming Group's net income?

Pharming Group reported net income of $2.5M in fiscal 2025, a net margin of 1.0%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.